Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
Rhea-AI Summary
Voyager Acquisition Corporation (NASDAQ: VACH) announced redemption results tied to its business combination with VERAXA Biotech AG on March 11, 2026. Holders of 25,217,315 Class A shares elected redemption, representing approximately 99.67% of Class A shares outstanding. After redemptions, about $885,556 will remain in the company's trust account and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG.
The announced redemptions will be processed pursuant to the redemption option and the submitted shares were not withdrawn.
Positive
- Approximately 99.67% of Class A shares submitted for redemption
- 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG
Negative
- Only $885,556 remains in the company's trust account after redemptions
- Extensive redemptions leave a minimal continuing public share interest in Voyager
News Market Reaction – VACH
On the day this news was published, VACH gained 14.68%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -26.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $56M to the company's valuation, bringing the market cap to $439.27M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VACH showed a modest -0.47% move pre-announcement while peers were mixed: one down (FERA -0.10%), two up (POLE +0.09%, BEAG +0.76%) and others flat. This pattern points to stock-specific factors rather than a coordinated SPAC/biotech shell move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jul 17 | F-4 filing update | Positive | +0.0% | Form F-4 filed detailing VERAXA merger terms and pro forma equity value. |
| Apr 23 | Deal announcement | Positive | +0.5% | Definitive business combination agreement to create Nasdaq-listed oncology company. |
Acquisition-related news around the VERAXA deal has produced limited but mixed reactions: one flat session and one modestly positive move, suggesting the stock has not consistently rerated on transaction milestones.
Over the last year, Voyager’s key news flow centered on its business combination with VERAXA Biotech AG. On Apr 23, 2025, it announced a definitive business combination agreement valued at a pre-money equity value of $1.3 billion, with access to up to $253 million in trust cash. On Jul 17, 2025, the parties filed a Form F-4 registration statement, detailing a pro forma equity value of $1.64 billion. Those milestones saw muted to modestly positive price moves, providing context for today’s redemption-heavy closing update.
Historical Comparison
In prior VERAXA-related acquisition updates, VACH’s average move was about 0.24%, indicating historically modest price reactions to major transaction milestones.
The transaction history shows a progression from signing the business combination agreement, to filing and effectiveness of the Form F‑4, and now to closing mechanics where nearly all public shares redeem and a small residual converts into VERAXA Biotech Holding AG.
Market Pulse Summary
The stock surged +14.7% in the session following this news. A strong positive reaction aligns with the culmination of Voyager’s long-running VERAXA transaction. The article confirms that 25,217,315 Class A shares, or 99.67% of the float, elected redemption, leaving only 82,685 shares to convert and about $885,556 in trust. Historically, acquisition milestones around this deal led to modest moves, so a sharp rally would mark a departure from prior muted trading.
Key Terms
trust account financial
business combination financial
business combination agreement financial
AI-generated analysis. Not financial advice.
BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Company's Class A ordinary shares (“Class A shares”) exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately
About the Business Combination
On April 22, 2025, VERAXA entered into the Business Combination Agreement, as amended. Upon closing of the Business Combination, the combined company is expected to become a publicly traded company listed on NASDAQ trading under the symbol “VRXA”.
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.
For regular updates about VERAXA Biotech, visit www.veraxa.com. You can also follow us on LinkedIn.
About Voyager Acquisition Corp.
Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry.
For more information, please visit https://www.voyageracq.com.
Participants In the Solicitation
Voyager, VERAXA, and their respective directors, executive officers, other members of management, and employees may be deemed participants in the solicitation of proxies from Voyager’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Voyager’s directors and officers in Voyager’s filings with the Securities and Exchange Commission (the “SEC”), including the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to VERAXA’s directors and executive officers is also included in the proxy statement/prospectus. You may obtain free copies of these documents as described below under the heading “Additional Information and Where to Find It.”
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Voyager or VERAXA, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release includes certain statements that may be considered forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements about future events or Voyager’s or VERAXA’s future financial or operating performance. For example, statements regarding VERAXA’s anticipated growth and the anticipated growth and other metrics, statements regarding the benefits of the Business Combination, and the anticipated timing of the completion of the Business Combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.
These forward-looking statements regarding future events and the future results of Voyager and VERAXA are based on current expectations, estimates, forecasts, and projections about the industry in which VERAXA operates, as well as the beliefs and assumptions of Voyager’s management and VERAXA’s management. These forward-looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Voyager relating to its initial public offering filed with the SEC, and in the proxy statement/prospectus filed by Voyager and VERAXA on February 19, 2026, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Voyager; (ii) uncertainties; (iii) assumptions; and (iv) other factors beyond Voyager’s or VERAXA’s control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, VERAXA’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Voyager and VERAXA therefore caution against relying on any of these forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Voyager and its management and VERAXA and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Voyager’s or VERAXA’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Voyager, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (v) other risks and uncertainties set forth in the filings by Voyager with the SEC. There may be additional risks that neither Voyager nor VERAXA presently know or that Voyager and VERAXA currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Any forward-looking statements made by or on behalf of Voyager or VERAXA speak only as of the date they are made. None of Voyager or VERAXA undertakes any obligation to update any forward-looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.
Additional Information and Where to Find It
In connection with the Business Combination Agreement, Voyager and VERAXA have filed a proxy statement/prospectus of Voyager, and will file other documents regarding the proposed transaction with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the proposed transaction. The definitive proxy statement and other relevant materials for the proposed transaction have been mailed or made available to stockholders of Voyager as of a record date to be established for voting on the proposed transaction.
Before making any voting or investment decision, investors and stockholders of Voyager are urged to carefully read the entire registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Voyager, VERAXA, and the proposed transaction. Voyager’s investors and stockholders and other interested persons can also obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Voyager and/or VERAXA in connection with the transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Voyager at the address set forth below.
Contact
| VERAXA Biotech AG | Voyager Acquisition Corp. | |
| Dr. Christoph Antz CEO Email: antz@veraxa.com | Mr. Adeel Rouf CEO, and Director Email: adeel@voyageracq.com | |
| For Media and Investors Mario Brkulj Valency Communications Email: mbrkulj@valencycomms.eu |
